Oragenics to Highlight Promising Concussion Treatment in Upcoming Webinar

Biotechnology company Oragenics will host a management update webinar focused on its innovative concussion treatment program, presenting details about its lead candidate ONP-002 and addressing critical unmet medical needs in traumatic brain injury management.

The webinar, scheduled for Tuesday, May 20, 2025, at 4:00 p.m. ET, will feature key leadership including CEO Janet Huffman, Chief Medical Officer Dr. James Kelly, and Chief Clinical Officer Dr. Frank Peacock, a renowned national emergency medicine expert. Presenters will discuss the company's intranasal therapy currently undergoing Phase IIa clinical trials for mild traumatic brain injury (mTBI).

Preliminary preclinical research suggests ONP-002 demonstrates significant potential in reducing brain inflammation and swelling, critical factors in concussion treatment. The intranasal delivery method represents an innovative approach to addressing neurological trauma, potentially offering patients a more targeted and efficient treatment option.

Mild traumatic brain injury represents a substantial healthcare challenge, affecting millions of individuals annually through sports injuries, accidents, and military service. Current treatment strategies often rely on rest and symptom management, with limited pharmaceutical interventions addressing the underlying neurological damage.

By developing an intranasal therapy targeting brain inflammation, Oragenics is positioned at the forefront of neurology research. The company's approach could represent a paradigm shift in concussion management, potentially reducing long-term neurological complications and improving patient outcomes.

The upcoming webinar provides an opportunity for investors, medical professionals, and researchers to gain insights into the company's progress and the potential implications of ONP-002 in treating mild traumatic brain injury.